Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revusiran in TTR Cardiac Amyloidosis
NCT01981837Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of revusiran in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation up to 63 days. Started Dec 2013; status: completed.
02
Drugs
revusiran
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT01981837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981837.